An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non–small cell lung cancer via persistent activation of ERK signalling
- 8 September 2017
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 85, 95-105
- https://doi.org/10.1016/j.ejca.2017.07.025
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR MutationJournal of Thoracic Oncology, 2015
- B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancerOncotarget, 2014
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancerAnnals of Oncology, 2014
- BAG-1 suppresses expression of the key regulatory cytokine transforming growth factor β (TGF-β1) in colorectal tumour cellsOncogene, 2012
- Reactivation of ERK Signaling Causes Resistance to EGFR Kinase InhibitorsCancer Discovery, 2012
- BAG-1 overexpression attenuates luminal apoptosis in MCF-10A mammary epithelial cells through enhanced RAF-1 activationOncogene, 2009
- Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLCNature Reviews Clinical Oncology, 2009
- EGFR inhibitors: what have we learned from the treatment of lung cancer?Nature Clinical Practice Oncology, 2005
- Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancerCurrent Oncology Reports, 2005
- Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor BiologyJournal of Clinical Oncology, 2005